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Thymus-derived murine cytotoxic effector cells generated to viral or chemically modi- 
fied autologous cells have been shown to selectively lyse target cells expressing the same 
H-2  serological regions as the  stimulator cells (1-11).  In vivo, the cytotoxic effectors 
generated to lymphocytic choriomeningitis (LCM) 1 (2, 3, 5), ectromelia (4), or vaccinia (8) 
viral-infected autologous components were demonstrated to be specific only for target 
cells expressing in common with the stimulator cell at least one H-2 serological region (2- 
5,  8) and infected with the  same or a  cross-reacting virus (8). In vitro, cell-mediated 
lympholysis (CML) reactions were generated by sensitization with trinitrophenyl (TNP)- 
modified autologous spleen cells (1, 6, 7). Splenic target cells were lysed by the effectors 
only if they were homologous with the stimulating cells at the K and/or D regions of  H-2, 
and if they were modified with TNP (1, 6, 7, 9). 
Since a  number of viruses have now been shown to elicit cytotoxic reactions 
with  this  type  of H-2  and  viral-associated  specificity,  it  was  of interest  to 
determine whether other modifying agents known to possess haptenic functions 
in  antibody  production  would  stimulate  cytotoxic effector cells  with  similar 
specificity requirements. The modifying agent N-(3-nitro-4-hydroxy-5-iodophen- 
ylacetyl)-13-alanylglycylglycyl-(N) was chosen for this study since Koren et al. 
have demonstrated that cytotoxic T-effector cells can be generated in vitro to N- 
modified, H-2-matched autologous spleen cells (11). The results presented in this 
report demonstrate that the cytotoxic effector cells generated in vitro by sensiti- 
zation to N-modified autologous spleen cells are specific for N-modified target 
cells  expressing  K  and/or  D  serological specificities identical  to  those  of the 
1  Abbreviations used  in this paper:  ACK, ammonium  chloride lysing solution;  BSS, Hanks' 
balanced  salt solution;  CML, cell-mediated  lympholysis;  LCM, lymphocytic choriomeningitis; 
MHC, major histocompatibility  complex; N,  N-(3-nitro-4-hydroxy-5-iodophenylacetyl)-~-alanyl- 
glycyl-glycyl; PHA, phytohemagglutinin;  TNP, trinitrophenyl. 
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modified stimulating cells. Similar to the observations made in the autologous 
TNP-modified  model  (6,  7,  9),  the  CML  generated  in  certain  strains  were 
stronger to N-modified K  than to N-modified D-region products,  although the 
strain distribution patterns  of preferential reactivity  were different for the N 
and TNP models. Specificity for the modifying agent as well as for H-2K- and/or 
H-2D-region products was also demonstrated. 
Materials and Methods 
Mice.  All mice used in these experiments were 7-9-wk-old males. The B10 congenic strains 
were obtained from The Jackson Laboratory, Bar Harbor, Maine. The B10.A(2R),  B10.A(4R),  and 
B10.A(5R)  recombinant strains were obtained either from The Jackson Laboratory or were raised 
in our mouse colony from breeders obtained from The Jackson Laboratory or from Dr.  Donald 
Shreffler, Department of Human Genetics, University of Michigan, Ann Arbor, Mich. 
Tumor Cells.  All tumors used in these experiments were serially passed at 7-9-day intervals 
in ascitic fluid. The tumors used and the strain in which each was passed were as follows: EL4 (/4- 
2 ~) in C57BL16; P815 (11-2  ~) in DBA/2; LSTRA (H-2  d) in BALB/c; RDM-4 (H-2  k) in AKR/J; LAF-17 
(H-2  a) in B10.A. The cells were harvested 5-9 days after intraperitoneal injection and prepared as 
described below. 
N  Modification  of Spleen  and  Tumor Cells for Sensitization and Targets.  Tumor cells were 
obtained from the ascitic fluid of mice and filtered through nylon mesh to remove clumps. Fresh 
spleen cells were obtained from 7-9-wk-old male mice and suspended in Hanks' balanced salt 
solution (BSS) by gentle teasing with a blunt forceps. They were then aspirated through a syringe 
3-4 times and filtered with nylon mesh. Erythrocytes were removed by suspension in ammonium 
chloride lysing solution (ACK) for 2 min. The lymphocytes were washed once in BSS and given a 
final wash in phosphate-buffered  saline (PBS), pH 7.6. The stock reagent of N-azide was prepared 
as previously described (12, and footnote 2) and diluted to 0.04  M concentrations with dimethyl- 
formamide and stored at -50°C. For modification 15 ~1 of N azide, suspended in 0.25 ml PBS, pH 
7.6,  was added to the cell pellet which had previously been suspended in 1 ml PBS, pH 7.6.  The 
cells were incubated for 20 min at 37°C in a shaking water bath. The cells were then washed two 
times in BSS with 10% fetal calf serum. Cells to be used as targets were labeled with Na~5~CrO4 
(New England Nuclear, Boston, Mass.) for 30 min before either N or TNP modification by incuba- 
tion in a 37°C water bath. 
TNP Modification  of Spleen and Tumor Cells.  Cell suspensions were prepared as described 
above except that the final wash after ACK lysing was in BSS. The cell pellet was then suspended 
in 2 ml of a phosphate-buffered  solution of 10 mM 2,4,6-trinitrobenzene sulfonate (Pierce Chemical 
Co., Rockford, Ill.), pH 7.4,  and incubated in a  shaking water bath at 37°C for 10 min. The cell 
suspension was then washed twice in BSS supplemented with 10% fetal calf serum. 
In Vitro  Cell Culture  and Assay for Cytotoxic Cells.  Splenic lymphocytes were sensitized in 
vitro with N- or TNP-modified cells, as previously described for TNP (1). The culture medium was 
RPMI 1640 (Microbiological Associates, Bethesda, Md.) supplemented with 10% fetal calf serum 
(Microbiological Associates), 2 mM L-glutamine (National Institutes of Health Media Unit), 1 mM 
pyruvate (Microbiological Associates), 1 x  nonessential amino acids (Microbiological Associates), 
100  U/ml penicillin, 100 ~g/ml streptomycin, and 5  ×  10 -5 M 2-mercaptoethanol. After a  5-day 
incubation the cells were harvested and their cytotoxic activity measured as previously described 
(1). The  mean and standard error of the percentage of specific cytotoxicity was calculated as 
described elsewhere (13). An effector target ratio of 40:1 was used except where noted. Nonspecific 
lysis of modified cells was determined from the amount of 51Cr released from the appropriate 5~Cr- 
labeled target cells incubated for 4 h  with effector cells which were incubated 5 days with no 
stimulator cells divided by the maximal ~lCr release. Background lysis varied in these experi- 
ments from 15 to 50%. 
Phytohemagglutinin (PHA) Stimulation of Spleen  Cells.  A fresh spleen cell suspension was 
obtained by teasing the spleens with a blunt forceps, aspirating the cells through a  syringe, and 
2 Koren,  H.  S.,  J.  R.  Wunderlich,  and J.  K.  Inman.  1975. T  cell memory for the cytotoxic 
response to hapten-modified target cells. Submitted for publication. T.  G.  REHN,  G.  M.  SHEARER,  H.  S.  KOREN,  AND  J.  K.  INMAN  129 
then filtering the cells through nylon mesh.  The cells were washed once in BSS before being 
suspended at  a  concentration of 5  ×  l0  s per ml in RPMI  1640 culture media supplemented as 
described above plus ~1  /~g/ml  of PHA  (Burroughs  Welcome &  Co.,  Greenville,  N.  C.).  After 
incubation for 2, 3, or 4 days, the cells were harvested immediately before use as targets. 
Results 
Target Cell Sensitivity to Effectors Generated by Sensitization  with N-Modi- 
fied Autologous Spleen Cells.  Earlier studies of CML to TNP-modified autolo- 
gous  spleen  cells  indicated  that  appreciable  lysis  could  be  detected  to  TNP 
modified  tumor  or  TNP-modified H-2-matched  normal  spleen  cell  targets  at 
effector:target  ratios  of 20:1  (1,  6).  However,  at  similar  ratios,  effector cells 
generated to N-modified syngeneic spleen cells were consistently detected using 
N-modified, H-2-matched tumor targets, but only occasionally when N-modified 
spleen cells were used as targets (11).  To investigate the relative sensitivity of 
various  N-modified lymphoid  targets,  C57BL/10 and  B10.BR splenic  lympho- 
cytes were sensitized  to N-modified autologous spleen cells.  The effector cells 
generated  were assayed on N-modified fresh spleen cells, 48-72-h PHA-stimu- 
lated N-modified spleen cells, or N-modified lymphoid tumor cells, syngeneic or 
allogeneic to the responding and stimulating lymphocytes. The results,  shown 
in Table I, indicate that only modified targets homologous at H-2K and/or H-2D 
with the cells of the stimulating phase were lysed, and that N-modified tumor 
cells and  PHA-stimulated N-modified spleen cells were more effective targets 
than  unstimulated  N-modified  spleen  cells.  In  all  subsequent  experiments, 
spleen cell targets for CML were PHA-stimulated. 
Specificity  of Effector  Cells Requires  both H-2 Homology  and N  Modifica- 
tion.  To determine  the  specificity of effector cells generated  by sensitization 
with N-modified autologous spleen cells, a series of unmodified and N-modified 
target cells syngeneic or congenic to the cells of the sensitizing phase were tested 
at different effector:target ratios for susceptibility to lysis by C57BL/10 effector 
cells. The results, shown in Table II, indicate that N modification is required for 
the lysis of both C57BL/10 autologous spleen cell targets and H-2 matched tumor 
cell targets. The failure of C57BL/10 effector cells to lyse N-modified B10.D2 and 
P-815 target  cells demonstrates  a  requirement  for H-2 homology between the 
targets and the cells of the sensitizing phase, as well as N  modification. 
Mapping  of  Effector  Cell  Specificity  within  the  H-2  Complex.  Previous 
reports  have  demonstrated  that  in  vitro  induction  of CML to  TNP-modified 
autologous spleen cells resulted  in the generation  of effector cells which were 
specific for TNP-modified spleen target cells sharing K  and/or D  end serological 
specificities with the TNP-modified stimulator cells (6, 7, 9). In the present study 
four C57BL/10 congenic mouse strains  were used to determine whether similar 
H-2 serological region homology is required to obtain lysis of N-modified, PHA- 
stimulated  spleen targets.  Splenic lymphocytes from B10.BR,  B10.D2,  B10.A, 
and C57BL/10 donors were sensitized to N-modified autologous spleen cells. The 
effector cells generated after 5 days of culture were tested for lysis of syngeneic, 
congenic,  and  allogeneic  N-modified,  PHA-stimulated  spleen target  cells.  Re- 
sults  representative  of these effector cell  specificity experiments  are  summa- 
rized  in  Tables III-VI  of this  report.  The  first  three  columns  of these tables 
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TABLE  [ 
Induction of In Vitro Cytotoxicity  by N-Modified Autologous Spleen Cells to N-Modified 
Spleen Cells, PHA-Stimulated Spleen Cells, and H-2-Matched Tumor Cells 
Target cellH-2 re- 
Responding  Stimulating  Target cells  Specific lysis  gion common to 
cells  cells  responding and 
stimulating cells 
% +-SE 
C57BL/10  C57BL/10-N  B10-N  2.7  _+ 1.6  All of H-2 
(bbbbbb)  (bbbbbb)  (bbbbbb) 
EL-4-N  27.2  ±  1.7  All of H-2 
(bbbbbb) 
C57BL/10-N'  14.4  -+ 1.5  All of H-2 
(bbbbbb) 
B10.A-N'  4.2  +- 2.3  None 
(kkkddd) 
B10.BR-N'  7.7  -+ 2.3  None 
(kkkkkk) 
B10.D2-N'  4.2  -+ 1.1  None 
(dddddd) 
B10.BR  B10.BR-N  B10.BR-N  14.5  -  3.2  All of H-2 
(kkkkkk)  (kkkkkk)  (kkkkkk) 
RDM-4-N  26.0  -+ 4.8  All of H-2 
(kkkkkk) 
B10.BR-N'  22.2  -+ 3.1  All of H-2 
(kkkkkk) 
B10.A-N'  12.9  _+  1.5  K, I-A, I-B 
(kkkddd) 
C57BL/10-N'  1.5  _+ 2.0  None 
(bbbbbb) 
B10.D2-N'  1.9  -+ 3.0  None 
(dddddd) 
Effector:target ratio, 20:1. 
N', PHA stimulated, N-modified spleen cells. 
tively. The H-2  alleles for the various regions of H-2 are shown beneath each 
strain.  The fourth column gives the mean percent of specific cytotoxicity with 
standard errors of the means. The last column indicates the H-2 region common 
between the target cells and the responding and stimulating cells. 
Representative data of CML experiments obtained using B10.BR effector cells 
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TABLE II 
Necessity of  Both N Modification and H-2 Homology for L  ysis of  PHA-Stimulated Spleen 
Targets and Tumor Targets by C57BL/10 Effector Cells Sensitized by Autologous N- 
Modified Spleen Cells 
Target cell 
Specific lysis at effector:target  ratio of: 








C57BL/10  (-)0.6 ±  2.0  2.2 ±  1.7  0.5  ±  1.4  (-)0.6 ±  2.1  1.5  ±  2.3  All of H-2 
(bbbbbb) 
C57BL/10-N  0.1  ±  4.4  6.6  ±  2.7  15.4  ±  3.1  15.8  ±  2.7  24.0  -+ 2.2  All of H-2 
(bbbbbb) 
EL-4  (-)1.1 _* 0.7  0.4 ±  0.4  (-)2.6 ±  0.8  (-)5.0 ±  0.9  (-)3.0 ±  1.0  All of H-2 
(bbbbbb) 
EL-4-N  10.6 ±  0.8  16.7  ±  0.6  25.2  -+  1.5  31.4  ±  2.5  41.2  ±  1.9  All of H-2 
(bbbbbb) 
B10.D2-N  3.5 -+ 2.1  (-)2.4 ±  2.2  1.1  ±  2.2  2.6  ±  2.4  7.5 ±  1.2  None 
(dddddd) 
PS15-N  (-)0.5 ±  1.3  0.9 ±  0.6  0.1  ±  0.6  2.4  ±  0.2  4.0 ±  1.2  None 
(dddddd) 
cells  are  summarized  in Table  III.  Unmodified B10.BR target  cells were not 
lysed by the effector cells, whereas N-modified syngeneic targets were lysed. N- 
modified B10.A and  B10.A(2R) spleen cells,  which share K, I-A,  and I-B H-2 
regions  with  B10.BR were effective targets.  The  lysis of modified  B10.A(4R) 
targets further localizes one area of homology to the K  and I-A regions of H-2. 
The lower but significant lysis of the noncongenic C3H. OH-N targets by B10.BR 
effectors localizes a second region of H-2 homology to the D  region of the major 
histocompatibility complex (MHC).  The above results contrast to the modified 
congenic B10.D2 and B10.A(5R) targets, which were not lysed and which share 
no known major regions of H-2 homology with B10.BR responding and stimulat- 
ing cells. 
Effector cells generated from cultures of B10.D2 lymphocytes sensitized with 
B10.D2-N-modified spleen cells were also tested on a series of N-modified target 
cells. The results are shown in Table IV. N modification was required for lysis of 
H-2-matched  L-1210 tumor cells.  These effector cells  lysed both B10.A-N and 
B10.A(5R)-N target cells,  which share I-C, S,  and D  with B10.D2.  This speci- 
ficity was localized to the D  half of H-2 by the failure of these effectors to lyse 
B10.A(2R)-N targets.  A  region of H-2  homology other than  the D  serological 
region is indicated by the  lysis of the noncongenic C3H.OH-N targets,  which 
share K, I-A, I-B, I-C,  and S  with B10.D2.  Other  congenic and  noncongenic 
spleen cells which share no known H-2 regions with B10.D2 were not effective 
targets. 
Lymphocytes from the B10. A strain, which shares the K, I-A, and I-B regions 
with  B10.BR and  the I-C,  S,  and D  regions  of H-2  with  B10.D2,  were  also 
sensitized  to  N-modified  autologous  spleen  cells and  tested on a  series  of N- 132  LYMPHOLYSIS  TO  N-MODIFIED  H-2K  AND  H-2D  PRODUCTS 
TABLE  III 
In Vitro Induction of Cytotoxicity of BIO.BR Spleen Cells to N-Modified Autologous 
Spleen Cells Assayed with N-Modified Syngeneic, Congenic, Allogeneic, or 
Recombinant Spleen PHA-Stimulated Target Cells 
Target cell H-2 
Responding  Stimulating  region common 




B10.BR  B10.BR-N  B10.BR  2.1  -+ 1.9  All of rio2 
(kkkkkk)  (kkkkkk)  (kkkkkk) 
B10.BR-N  23.1 +- 2.3  All of H-2 
(kkkkkk) 
B10.A-N  16.2  _+ 1.7  K, I-A, I-B 
(kkkddd) 
B10.A(2R)-N  24.2  _+  1.8  K, I-A, I-B 
(kkkddb) 
B10.A(4R)-N  19.1  ±  3.0  K, I-A 
(kkbbbb) 
C3H.OH-N  11.6 -+ 1.2  D 
(dddddk) 
B10.D2-N  (-)0.9  -+  1.3  None 
(dddddd) 
B10.A(5R)  0.2  ±  3.9  None 
(bbbddd) 
C57BL/10-N  1.1  -+ 0.6  None 
(bbbbbb) 
Effector:target ratio 40:1. 
modified targets (see Table V). The B10.A effector cells lysed B10.A-N, B10.BR- 
N, B10.A(2R)-N,  and B10.A(4R)-N to about the same extent. All of these targets 
share the K  and I-A  regions with B10.A.  B10.D2-N,  A.TL-N, and B10.A(5R)-N 
targets were also lysed by B10.A effectors, whereas C3H.OH-N targets were not. 
Finally,  C57BL/10-N  targets,  which  share  no  major H-2  regions  with  B10.A, 
were not significantly lysed. Taken together, these results identify two distinct 
regions of homology between B10. A responder and/or modified stimulating cells 
and  the  modified targets,  either  region  of which  is  necessary  for appreciable 
lysis:  one  involving K  or K  plus I-A  and  a  second  including D  or D  plus I-C 
and/or S. 
Sensitization  of C57BL/10  splenic  lymphocytes with  N-modified  autologous 
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TABLE IV 
In Vitro Induction of Cytotoxicity of BlO.D2 Spleen Cells to N-Modified Autologous 
Spleen Cells Assayed With N-Modified Syngeneic, Congenic,  Allogeneic,  or 
Recombinant Spleen PHA-Stimulated Target Cells 
Target cell H-2 region 
Responding  Stimulating  Target cells  Specific lysis  common  to responding 
cells  cells  and stimulating  cells 
% +-SE 
B10.D2  B10.D2-N  L1210  -0.4 -+ 1.4  All of H-2 
(dddddd)  (dddddd)  (dddddd) 
L1210-N  17.4 -+ 1.0  All of H-2 
(dddddd) 
B10.D2-N  15.0 -+ 4.6  All of H-2 
(dddddd) 
B10.A-N  12.4 -+ 1.2  I-C, S, D 
(kkkddd) 
B10.A(5R)-N  14.3  -+ 2.3  I-C, S, D 
(bbbddd) 
B10.A(2R)-N  (-)2.2 -+ 0.9  I-C, S 
(kkkddb) 
C3H.OH-N  14.3 -+ 2.3 
(dddddk) 
K, I-A, I-B, I-C, S 
B10.A(4R)-N  3.4 -+ 2.3  None 
(kkbbbb) 
C57BL/10-N  2.5  ±  1.5  None 
(bbbbbb) 
B10.BR-N  2.0 -+ 1.5  None 
(kkkkkk) 
SJL-N  2.4 -+ 2.2  None 
(ssssss) 
Effector:target ratio 40:1. 
targets (see Table VI). These targets respectively share all of H-2 or K, I-A, and 
I-B with the cells of the  sensitization phase.  A  lower but significant lysis was 
obtained using modified targets sharing either I-B, S,  and D  (B10.A[4R]) or D 
alone (B10.A[2R]) with C57BL/10.  B10.D2-N and B10.BR-N spleen cell targets 
were not lysed by C57BL/10 effectors. These results indicate that either one of 
two major regions of MHC  homology are also required  between the  modified 
target cells and the C57BL/10 responding and/or modified stimulating cells. 
Differential  Cytotoxic Reactivity of C57BL/10 Spleen Cells to K  and D  End 
Modified by TNP or N.  In a  previous study involving CML to TNP-modified 134  LYMPHOLYSIS  TO  N-MODIFIED  H-2K  AND  Ho2D  PRODUCTS 
TABLE  V 
In Vitro Induction of Cytotoxicity of  BlO.A Spleen Cells to N-Modified A utologous Spleen 
Cells Assayed with N-Modified Syngenic, Congenic, Allogeneic, or Recombinant Spleen 
PHA-Stimulated Target Cells 
Target cell H-2 region 
Responding  Stimulating  Target cells  Specific lysis  common to responding 
cells  cells  and stimulating cells 
% +SE 
B10.A  B10.A-N  LAF-N  19.7  _+  0.7  All of H-2 
(kkkddd)  (kkkddd)  (kkkddd) 
B10.A  0.5 _+  0.6  All of H-2 
(kkkddd) 
B10.A-N  19.1  _+  5.3  All of H-2 
(kkkddd) 
B10.BR-N  14.9  --- 1.0  K, I-A, I-B 
(kkkkkk) 
B10.A(2R)-N  12.4  _+  1.1  K, I-A, I-B, I-C, S 
(kkkddb) 
B10.A(4R)-N  18.6  -  1.5  K, I-A 
(kkbbbb) 
B10.D2-N  7.1  -+  1.2  I-C, S, D 
(dddddd) 
B10.A(5R)-N  7.6  -+  1.6  I-C, S, D 
(bbbddd) 
A.TL-N  8.0  --  1.0  I-A, I-B, D 
(skkkkd) 
C3H.OH-N  4.5  -+ 0.5  I-C, S 
(dddddk) 
C57BL/10-N  1.9  -+  1.1  None 
(bbbbbb) 
SJL-N  4.0  -+  1.7  None 
(ssssss) 
Effector:target ratio 40:1. 
autologous spleen cells,  C57BL/10 responding lymphocytes generated effector 
cells with equal reactivity toward TNP-modified H-2K and TNP-modified H-2D 
serological  region  products  (6). In  contrast,  it  was  consistently found  that 
C57BL/10  responding  lymphocytes generated  effector cells  which  exhibited 
greater reactivity to N-modified K-end than to N-modified D-end products (see 
Table VI). Table VII compares the differential cytotoxic reactivity of C57BL/10 
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TABLE  VI 
In Vitro Induction of Cytotoxicity of C57BL/10 Spleen Cells to N-Modified Autologous 
Spleen Cells Assayed with N-Modified Syngeneic, Congenic, AUogeneic, or 
Recombinant Spleen PHA-Stimulated Target Cells 
Target cellH-2 re- 
Responding  Stimulating  Target cells  Specific lysis  gion common to 
cells  cells  responding and 
stimulating cells 
% +_SE 
C57BL/10  C57BL/10-N  C57BL/10  0.1  ±  1.3  All of H-2 
(bbbbbb)  (bbbbbb)  (bbbbbb) 
C57BL/10-N  31.4  -+ 3.2  All of H-2 
(bbbbbb) 
B10.A(5R)-N  22.5  -+ 2.5  K, I-A, I-B 
(bbbddd) 
B10.A(4R)-N  13.7  -+ 2.6  I-B, I-C, S, D 
(kkbbbb) 
B10.A(2R)-N  10.1  -+  1.7  D 
(kkkddb) 
B10.D2-N  6.5  ~-  1.4  None 
(dddddd) 
B10.BR-N  4.4  -+  0.6  None 
(kkkkkk) 
Effector:target ratio 40:1. 
stimulating cells. These effector cells were assayed on target cells H-2 matched 
with the stimulating cell at the K  or D  end and modified with the same reagent 
to which the effector cell precursor had been stimulated.  These results verify 
that  equivalent  cytotoxic  reactivity  was  obtained  to  TNP-modified K-  or D- 
region products,  whereas stronger  lympholysis was detected to N-modified K- 
end products than to N-modified D-end products. 
Specificity of Lympholysis as a Function of the Modifying Agent.  To deter- 
mine whether the modifying agent plays a  significant role in the specificity of 
the cytotoxic reaction to modified autologous spleen cells, responding lympho- 
cytes  from  three  B10  congenic  mouse  strains  were  sensitized  to  autologous 
spleen cells modified either with TNP or N. The effector cells generated in each 
sensitization  were assayed separately on H-2-matched tumor targets  modified 
with either TNP or N. The results, summarized in Table VIII, demonstrate that 
effector cells generated  by sensitization  with autologous spleen cells modified 
with one of the reagents lyse only H-2-matched targets modified with the same 
reagent.  Thus,  no  cross-reactivity  was  detected  for  CML  generated  against 
TNP-modified and N-modified autologous spleen cells. 
Demonstration  that K  and~or D  Homology is Required  between N-Modified 
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TAeLE  VII 
In Vitro Induction of Differential Cytotoxic Reactivity of C57BL/10 Spleen Cells to 
Chemically-Modified K  and D Region Serological Products by Sensitization to either 
TNP- or N-Modified Autologous Spleen Cells 
Target  cellH-2 re- 
Responding  Stimulating cells  Target cells  Specific lysis  gion common to 
cells  responding and 
stimulating cells 
% +-SE 
C57BL/10  C57BL/10-TNP  B10.A(5R)-TNP  12.6 _+ 2.3  K, I-A, I-B 
(bbbbbb)  (bbbbbb)  (bbbddd) 
B10.A(4R)-TNP  12.2  ±  1.8  I-B, I-C, S, D 
(kkbbbb) 
B10.A(2R)-TNP  15.7 ± 2.1  D 
(kkkddb) 
C57BL/10-N  B10.A(5R)-N  14.4 ±  2.2 
(bbbbbb)  (bbbddd) 
K, LA, LB 
B10.A(4R)-N  2.8  ±  3.1 
(kkbbbb) 
I-B, I-C, S, D 
B10.A(2R)  6.6  ±  2.0  D 
(kkkddb) 
Effector:target  ratio 40:1 
homology at  the K  and/or D  serological regions  was  always present  among 
responding,  modified stimulating, and modified target cells when significant 
lysis was obtained. None of the results described ~hus far discriminate among 
the possibilities that the intra-H-2 homology obtained is required: (a) between 
responding lymphocytes and modified stimulating cells; (b) between responding 
lymphocytes and modified target cells; (c) between modified stimulating cells 
and modified target cells; or (d) among all three of these cell types. To investi- 
gate this problem, (C57BL/10  x  B10.BR)F1 responding lymphocytes were sensi- 
tized with C57BL/10,  B10.BR, or (C57BL/10  ×  B10.BR)F1  N-modified stimulat- 
ing cells. The effector cells generated were assayed on EL-4-N (H-2 b,  matched 
with C57BL/10) and on RDM-4-N (H-2 k, matched with B10.BR) target cells. The 
results are shown in Table IX. Effector cells sensitized with modified stimulat- 
ing cells from either parent lysed only modified target cells which were H-2 
matched  with the  modified stimulating cell  of that  parent.  These  data  are 
compatible only with possibilities (c) or (d). In contrast to the data obtained with 
splenic  lymphocytes from  the  parental  B10  congenic  strains,  (C57BL/10  x 
B10.BR)FI responding lymphocytes sensitized with FrN stimulating cells gener- 
ated effectors that resulted in the lysis of both N-modified  H-2 ° and H-2 k targets. 
A  similar experiment involving (B10.D2  ×  B10.BR)F1  responding lympho- 
cytes sensitized with B10.BR-N stimulating cells and assayed on RDM-4-N (H~2 
matched) and P-815-N  (H-2 unmatched with the stimulator) targets is shown in T.  G.  REHN,  G.  M.  SHEARER,  H.  S.  KOREN,  AND  J.  K.  INMAN  137 
TABLE  VIII 
Specificity of Cytotoxic Reactivity of BlO Congenic Spleen Cells as a Function  of either 
TNP or N Modification  of the Autologous  Sensitizing Spleen  Cells 
Responding cells  Stimulating cells  Target cells  Specific Lysis 
C57BL/10 
% +-SE 
C57BL/10-TNP  EL-4-TNP  47.6  -+  1.5 
EL-4-N  (-)1.8  -+  1.1 
C57BL/10-N  EL-4-TNP  1.8  -+ 2.1 
EL-4-N  26.1  -  1.2 
B10.BR  B10.BR-TNP  B10.BR-TNP  44.0  -+ 2.8 
B10.BR-N  2.5  +-- 1.7 
B10.BR-N  B10.BR-TNP  3.6  +  1.5 
B10.BR-N  24.4  +-  1.7 
B10.D2  B10.D2-TNP  LSTRA-TNP  13.5  -+  1.5 
LSTRA-N  (-)2.0  -+  1.8 
B10.D2-N  LSTRA-TNP  2.6  -+  1.0 
LSTRA-N  10.7  -+  2.0 
Effector:target ratio 20:1 
Table X.  These data confirm the results of the previous experiment,  since the 
effector cells generated lysed RDM-4-N but not P-815-N target cells. In addition, 
an attempt was made to block the lytic phases with non-5'Cr-labeled modified 
and unmodified RDM-4 and P-815 cells. An appreciable reduction in lympholysis 
was observed only when the effectors were preincubated for 30 min with the N- 
modified H-2-matched RDM-4 cells. 
Discussion 
The results presented in the first six tables of this report consistently demon- 
strated that the cytotoxic specificity of effector cells generated in a  CML to N- 
modified autologous spleen cells involved both H-2 serological region homology 
and N  modification of both stimulating and target cells. By testing the effector 
cells on N-modified targets differing from the responding and stimulating cells 
within H-2,  it was possible to identify two distinct H-2 regions in each inbred 
strain toward which the specificity was directed. 
The mapping studies of effector cell specificity to N-modified autologous cells 
presented here are similar to those reported earlier using TNP-modified autolo- 
gous cells (6, 9). Effector cells from the B10.BR (Table III) and B10.A (Table V) 
strains  sensitized  to  N-modified  autologous  spleen  cells  exhibited  cytotoxic 
specificity to N-modified targets sharing K  or K  plus I-A  with the cells of the 
stimulating phase.  A significant but lower level of reactivity was generated to 
N-modified  targets  sharing  H-2D  in  the  case  of B10.BR  and  to  N-modified 
targets sharing alleles in the D  half of H-2 in the case of B10.A. It is interesting 
that reactivity to N-modified targets sharing K  end was greater than that to N- 
modified targets sharing D  end. This pattern of preferential reactivity to K  end 
is  similar  to  that  observed  for  CML  in  these  two  strains  to  TNP-modified 
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TABLE IX 
In Vitro Induction of Cytotoxicity of (C57BL/10 x BIO.BR)F~ Spleen Cells by C57BL/10, 
BIO.BR, or (C57BL/10 x BIO.BR)F~ N-Modified Spleen Cells Assayed with N-Modified 
Tumor Cells 
Responding cells  Stimulating cells  Target cells  Specific  lysis 
Target cell homol- 
ogy with: 
Respond-  Stimulat- 
ing cells  ing cells 
(C57BL/10  x  B10,BR)F~  C57BL/10~N  EL-4-N 
b~  (bbbbbb)  (bbbbbb) 
BIO.BR-N 
(kkkkkk) 
(C57BL/10  x  B10.BR)FrN 
bbbbbb ] 
%±SE 
39.1  ± 2.2  Yes  Yes 
RDM-4-N  4.0  ±  2.0  Yes  No 
(kkkkkk) 
RDM-4-N  21.9  ± 3.7  Yes  Yes 
(kkkkkk) 
EL-4-N  8.0  ±  1,0  Yes  No 
(bbbbbb) 
EL-4-N  18.7 ±  1.3  Yes  Yes 
(bbbbbb) 
RDM-4-N  14.2  ±  1.6  Yes  Yes 
(kkkkkk) 
Effector:target ratio 20:1 
B10.D2 effector cells were demonstrated to  exhibit  significant cytotoxicity 
toward N-modified targets sharing one or two H-2 regmns with the responding 
or stimulating cells (Table IV). As shown by the use of N-modified recombinant 
congenic strains, the regions probably involved D  alone and some regions not 
including D,  presumably the K  serological region as shown by the  C3H.OH 
targets. Again, these B10.D2 data quantitatively resemble those obtained with 
TNP-modified autologous spleen cells in that  equal cytotoxic reactivity was 
detected toward K or D-matched N-modified targets. The level of cytotoxicity of 
B10.D2 effector cells was lower than that generated by B10.BR and B10.A to 
their respective N-modified targets, as was seen in the TNP system (6, 9). 
Responder lymphocytes from C57BL/10 mice generated effector cells which 
lysed N-modified targets homologous with the cells of the stimulating phase at 
K, I-A, and I-B or at the D serological region (Table VI). However, in contrast to 
the TNP-autologous CML in which C57BL/10 effector cells lysed equally well 
TNP-modified target cells matched at the K  or D  end with the cells of the 
sensitization phase (upper part of Table VII),  the N-autologous CML in this 
strain lysed N-modified targets matched at the K end greater than N-modified 
targets  matched at the D  end  (lower part  of Table  VII).  These differential 
patterns  of reactivity could be  due to differences in  immunogenicity of the 
antigenic specificities associated with the K  and D  ends and/or to H-2-1inked 
immune response genes controlling reactivity to these specificities. The data 
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TABLE X 
In Vitro Induction of Cytotoxicity of (BIO.D2 × BIO.BR)FI Spleen Cells by N-Modified 
BIO.BR Spleen Cells Assayed with N-Modified Tumor Targets: Blocking of Effector 
Cells with H-2-Matched Nonradioactive  Tumor Cells 
Reduc- 
Stimulating  Blocking  Target 
Responding cells  cells  cells  cells  Specific  lysis  tiOntotoxic.in  cy- 
ity* 
(B10.D2 x B10.BR)F,  B10.BR-N  --  P815-N 
dddddd ~  (kkkkkk)  (dddddd) 
kkkkkk] 
% +-SE  % 
2.5 -+ 0.9 
RDM-4-N  30.4 -+ 2.2 
(kkkkkk) 
P815  RDM-4-N  27.9 -+ 2.0 
(dddddd)  (kkkkkk) 
P815-N  RDM-4-N  29.3  -+ 1.4  (-)5.0 
(dddddd)  (kkkkkk) 
RDM-4  RDM-4-N  23.6 -+ 2.1 
(kkkkkk)  (kkkkkk) 
RDM-4-N  RDM-4-N  13.6 -+ 1.0  42.4 
(kkkkkk)  (kkkkkk) 
Effector:target ratio 40:1. 
Blocking cell:target  ratio 20:1. 
* Percent reduction in cytotoxicity equals percent specific  lysis  in presence of  unmodified blocking 
cells  minus percent specific  lysis  in  presence of  modified blocking cells  divided by percent specific 
lysis  in presence of  unmodified blocking cells. 
published report indicates that differential reactivities to TNP-modified K  and 
D  region products involves both immune response genes acting at the level of 
the responder lymphocytes and differential immunogenicity at the level of the 
stimulating cell (7). Studies using F1 and recombinant animals are currently in 
progress to investigate these possibilities in the N  system. 
Since it was necessary to modify the target cells to obtain lysis by effector cells 
generated  by chemically-modified  autologous  spleen  cells  (1,  6,  7,  9,  11  and 
Tables II-VI), the specificity requirements of the N and TNP modifying agents 
were  investigated.  The  results  of Table  VIII  demonstrate  that  effector cells 
generated  by sensitization  with TNP-modified autologous cells do not lyse N- 
modified syngeneic targets and vice versa. These findings are compatible with 
one of three possibilities: (a) that "hapten specificity" is involved and that H-2 
homology is required between effector and target cells by cell-to-cell interaction 
requiring H-2 identity possibly similar to that reported by Katz et al. for anti- 
body production (14); (b) that these modifying agents induce distinct and specific 
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do not themselves compose part of the antigenic structure; or (c) that TNP and N 
constitute  integral  components of a  new antigen  created by the  modification 
that involves altered H-2 serological region products. 
The  possibility  of a  major  "hapten-specific"  CML  with  intra  H-2  identity 
required  for  effector-target  cell  interaction  can  be  excluded  by  the  F1  data 
presented in Tables IX and X. If possibility (a) were correct, then F1 effector cells 
generated  by sensitization  with  N-modified  cells  from  either  of the  parents 
should have lysed N-modified targets from both parents. These findings demon- 
strate that intra-H-2  homology is required between N-modified stimulator and 
N-modified  target  cells,  or  among  responding,  stimulating,  and  target  cells. 
This experimental design and the conclusions drawn are similar to other exam- 
ples of CML to viral  (3,  4,  8)-  and  chemically  (6,  9)-modified autologous cell 
models. 
While possibility (b) cannot be evaluated by data presented in this report, the 
observations that TNP- and N-modified chicken erythrocytes block effector cell 
lysis of the appropriate  TNP- or N-modified target cells, respectively (15,  and 
Koren,  unpublished observations) suggest that these moieties may be integral 
components of new antigens created by modification of H-2 products. However, 
the demonstration that unmodified chicken red blood cells will not block while 
chemically-modified chicken red blood cells do block does not prove specificity. 
The blocking could be due to a nonspecific toxic effect of the modified chicken red 
blood cells. For instance,  it must be shown that TNP chicken red blood cells do 
not block other cytolytic reactions such as an  allogeneic CML or preferably a 
CML model more similar to the N  system.  Koren (manuscript  in preparation) 
has found such controls difficult to obtain reproducibly. In contrast to modified 
chicken red blood cell blocking, inhibition with chemically-modified spleen cells 
occurs only when there is H-2 homology among stimulating,  target,  and block- 
ing cells  (6,  and  Table  X).  It is not understood  at the  present time  why H-2 
homology is required for blocking of lysis by modified spleen cells, whereas no 
such homology appears to be necessary for blocking by modified chicken erythro- 
cytes. 
The data available in the N modification system as well as other systems (3, 4, 
6, 8,  9,  16) are compatible with the hypothesis that certain viral and chemical 
agents  can  modify H-2-related  cell  surface  components  (possibly  serological 
region  products)  to  create  new antigenic  determinants.  These  "neo-self anti- 
gens" appear to include as part of the viral (3, 4, 6, 8, 16) or chemical (6, 9) recog- 
nition structure the respective modifying agent. 
The (C57BL/10 × B10.BR)F1 responding lymphocytes sensitized to N-modified 
autologous F1 cells generated  a broader range  of effector cell specificities than 
would either  of the  homologous parents  (Tables IX,  III,  VI).  If an  expanded 
range  of cytotoxic specificities  were  advantageous  for  survival,  as  might  be 
expected in a viral model (17), then a selective pressure for pelymorphism in the 
MHC  would  exist  (6,  17).  Such  a  pressure  could be  exerted  by functionally 
distinct  H-2  products  at  the  level  of formation  of the  new antigen  (modified 
serological  region  products)  and/or  at  the  level  of response  potential  to  that 
antigen (immune response genes). T.  G.  REHN,  G.  M.  SHEARER,  H.  S.  KOREN,  AND  J.  K.  INMAN  141 
Summary 
Splenic lymphocytes from four C57BL/10 congenic mouse strains were sensi- 
tized in vitro  to N-(3-nitro-4-hydroxy-5-iodophenylacetyl)-fl-alanylglycylglycyl- 
(N) modified autologous lymphocytes. The effector  cells  generated after  5 days of 
culture were assayed on a series of either N-modified phytohemagglutinin- 
stimulated spleen cells  or N-modified tumor cells.  The results  indicated in all 
cases that both N  modification of the targets and H-2 homology between the 
modified stimulating  and target cells  are  required  for  lysis  to  occur.  In each case 
the effector  cells  were found to lyse  N-modified target cells  only when there was 
homology at either  or  both ends of  the major histocompatibility  complex (MHC) 
between the stimulator and target cells.  B10.BR lysed  targets  sharing alleles  at 
K  (or  K  plus  I-A)  and/or at  D. B10.A effector  cell  specificity  was mapped to  K  (or 
K  plus I-A)  and/or the D  half  of  the MHC  (D or  D  plus I-C and/or S). The two 
regions of  specificity  determined for B10.D2 effector  cells  were D  (or  D  plus S 
plus  I-C)  and a region not including  D  of  the MHC.  C57BL/10 effector  cells  lysed 
N-modified targets only if  there was target cell  H-2 homology at  K, I-A,  and  I-B 
or  at the  D  serological  region. As in  the trinitrophenyl (TNP) system (6)  B10.BR 
and B10.A effector  cells  lysed targets sharing K  end H-2 serological  regions 
greater than target cells  sharing  D-end serological  regions.  The C57BL/10 effec- 
tor  cells  were shown to  react  to  the  K end greater than the  D end, which differed 
from the equal reactivity  seen in the TNP  system for this  strain.  The data are 
consistent with the hypothesis that the antigen recognized by the effector  cell 
includes an altered H-2 serological  cell  surface product. That the reaction is  not 
"hapten specific"  and the H-2 homology is required only for effector:target  cell 
interaction  was excluded by  the  use of  two FI combinations in  which lysis  of  only 
N-modified target  cells  sharing the  H-2 haplotype with  the  stimulating  parental 
strain  was obtained. Finally,  it  was demonstrated that N and TNP modification 
create distinct  new antigenic determinants, since  an effector  cell  sensitized  to 
one modifying agent will lyse only H-2-matched target modified with that same 
modifying agent. 
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